3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Withdrawn
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polyps
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Radiotherapy
91
pembrolizumab
88
Cyclophosphamide
84
Gemcitabine
70
Cisplatin
70
Magnetic Resonance Spectroscopy
65
Carboplatin
60
Radiosurgery
55
Paclitaxel
55
Nivolumab
48
Dexamethasone
45
Bevacizumab
42
Biopsy
41
Fluorouracil
39
durvalumab
37
Surveys and Questionnaires
36
Docetaxel
36
fludarabine
35
Doxorubicin
35
Radiation
33
Oxaliplatin
33
Capecitabine
33
Rituximab
32
fludarabine phosphate
31
Leucovorin
31
Cytarabine
30
Melphalan
29
Etoposide
28
Pemetrexed
27
Irinotecan
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
OTHER
×
eicosapentaenoic acid ethyl ester
×
Clear all
NCT03661047
2021-11-17
OMICC
Massachusetts General Hospital
Phase 2
Withdrawn